Wall Street analysts expect Allakos Inc (NASDAQ:ALLK) to post earnings of ($0.50) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Allakos’ earnings, with estimates ranging from ($0.50) to ($0.49). Allakos posted earnings per share of ($0.35) during the same quarter last year, which indicates a negative year over year growth rate of 42.9%. The firm is scheduled to issue its next earnings results on Thursday, March 12th.
On average, analysts expect that Allakos will report full-year earnings of ($1.88) per share for the current year, with EPS estimates ranging from ($1.88) to ($1.87). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.58) per share, with EPS estimates ranging from ($2.98) to ($2.17). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Allakos.
Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Redmile Group LLC increased its holdings in shares of Allakos by 33.8% in the third quarter. Redmile Group LLC now owns 3,077,128 shares of the company’s stock valued at $241,955,000 after purchasing an additional 776,827 shares in the last quarter. BlackRock Inc. increased its stake in shares of Allakos by 8.9% in the 2nd quarter. BlackRock Inc. now owns 1,867,040 shares of the company’s stock valued at $80,900,000 after buying an additional 152,634 shares during the period. Vanguard Group Inc. increased its stake in shares of Allakos by 5.4% in the 2nd quarter. Vanguard Group Inc. now owns 1,735,254 shares of the company’s stock valued at $75,188,000 after buying an additional 88,745 shares during the period. State Street Corp increased its stake in shares of Allakos by 141.2% in the 3rd quarter. State Street Corp now owns 767,711 shares of the company’s stock valued at $60,365,000 after buying an additional 449,407 shares during the period. Finally, Northern Trust Corp raised its position in shares of Allakos by 2.3% during the second quarter. Northern Trust Corp now owns 170,143 shares of the company’s stock worth $7,372,000 after acquiring an additional 3,847 shares during the last quarter. 68.68% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:ALLK traded down $0.04 during midday trading on Tuesday, reaching $95.94. The company’s stock had a trading volume of 205,991 shares, compared to its average volume of 431,195. Allakos has a fifty-two week low of $30.32 and a fifty-two week high of $98.37. The company has a market capitalization of $4.62 billion, a P/E ratio of -43.61 and a beta of -1.13. The business’s fifty day simple moving average is $77.30 and its 200-day simple moving average is $63.68.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Further Reading: What is the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.